NDA 214998 · Bristol
Camzyos
Mavacamten · Oral · Cardiac Myosin Inhibitor
NovelBreakthrough therapyOrphanCDER novel approval, Apr 28, 2022: To treat certain classes of obstructive hypertrophic cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Apr 28, 2022
Approved uses
4
Original approval plus efficacy supplements
Registered trials
26
8 Phase 3, 12 recruiting
FAERS reports
6,048
2,643 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEART FAILURE CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction [see Warnings and Precautions (5.1) ] . Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ] . Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following [see Contraindications (4) and Warnings and Precautions (5.2) ] : • Strong CYP2C19...
What it is approved for
From the label in effect Sep 30, 2026.
CAMZYOS is indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms . CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults and pediatric patients weighing 30 kg or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. ( 1 )
Mechanism: Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with mavacamten reduces dynamic LVOT...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 2026 Supplement 13 · Efficacy · priority review OrphanLetterLabel
- Apr 17, 2025 Supplement 10 · Efficacy OrphanLabelLetter
- Jun 15, 2023 Supplement 1 · Efficacy OrphanLabelMedication GuideLetter
- Apr 28, 2022 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
5 products under this application
- CAMZYOS · MAVACAMTEN 2.5MG · CAPSULE, ORAL · Prescription
- CAMZYOS · MAVACAMTEN 15MG · CAPSULE, ORAL · Prescription
- CAMZYOS · MAVACAMTEN 5MG · CAPSULE, ORAL · Prescription
- CAMZYOS · MAVACAMTEN 1MG · CAPSULE, ORAL · Prescription
- CAMZYOS · MAVACAMTEN 10MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mavacamten" as an intervention, any sponsor and status, largest first.
- A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05582395 · 580 participants · Start Dec 14, 2022 · Primary completion Mar 6, 2025
Drug: Mavacamten · For: Cardiomyopathy, Hypertrophic
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 224 sites in all
- A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)Pivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07940777 · 500 participants (planned) · Start Dec 29, 2026 · Primary completion Jul 21, 2029
Drug: Mavacamten · For: Non-obstructive Hypertrophic Cardiomyopathy
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03723655 · 314 participants · Start Sep 27, 2018 · Primary completion Jan 16, 2026
Drug: mavacamten · For: Hypertrophic Cardiomyopathy; Obstructive Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic Cardiomyopathy
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 68 sites in all
- Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten TherapyPivotal-lookingNot yet recruiting
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07815301 · 286 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Beta-Blocker Sequential Tapering and Discontinuation; Beta-Blocker Baseline Stable-Dose Maintenance · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Wenzhou, China
- Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyPivotal-lookingCompleted
MyoKardia, Inc.Bristol Myers Squibb (BMY)
NCT03470545 · 251 participants · Start May 29, 2018 · Primary completion Mar 14, 2020
Drug: mavacamten; Placebo · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 71 sites in all
- A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05362045 · 158 participants · Start May 16, 2022 · Primary completion Aug 19, 2022
Drug: Mavacamten · For: Healthy Participants
Sites: Miami, Florida; Springfield, Missouri; Austin, Texas · 4 sites in all
- The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular ObstructionEnrolling by invitation
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07103655 · 132 participants (planned) · Start Mar 1, 2026 · Primary completion Nov 1, 2026
Drug: mavacamten; Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol and 1 more · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Hangzhou, China
- Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNot yet recruiting
Second Affiliated Hospital of Nanchang UniversityAcademic, hospital or other
NCT07807384 · 115 participants (planned) · Start Nov 2026 · Primary completion Sep 2029
Drug: Mavacamten · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue442
- dyspnoea427
- atrial fibrillation370
- product dose omission issue362
- dizziness353
- product use issue268
- off label use230
- ejection fraction decreased224
- therapy interrupted196
- chest pain194
- palpitations182
- headache174
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 390 |
| 2023 | 825 |
| 2024 | 1,052 |
| 2025 | 1,458 |
| 2026 | 2,323 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Camzyos (Mavacamten)
2024 spending
$291M
Beneficiaries
4,490
35,896 claims
Per beneficiary
$64,772
$272.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $8,095,504 |
| 2023 | $105,090,144 |
| 2024 | $290,825,667 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I, Oreziak A, Barriales-Villa R, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Owens AT, Abraham T, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Davis BJ, Volk H, Nguyen O, et al. · J Am Heart Assoc 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.
Rossano JW, Canter C, Wolf CM, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
Heitner SB, Jacoby D, Lester SJ, et al. · Ann Intern Med 2019 · Clinical Trial, Phase II, Multicenter Study
- Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.
Aman A, Akram A, Akram B, et al. · Open Heart 2025 · Systematic Review, Meta-Analysis
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.